French health insurer ALAN surpasses €1 billion in total funding as PROSUS joins its shareholder base

French scale-up Alan has reportedly raised €480 million from investment group Prosus in a transaction that would value the company at €5.5 billion. Coming just three months after a €100 million financing round, the transaction would be one of Europe’s largest fundraisings this year outside generative AI and would take the company’s total funding to more than €1.2 billion.

At first glance, the operation may appear surprising. Alan reports more than 1.1 million members, growth exceeding 50%, close to €800 million in annualised recurring revenue in the first quarter and a target of surpassing €1 billion in ARR by the end of the year. The company also says it has reached profitability in France, and nothing suggests that it is facing the kind of cash pressure affecting many European scale-ups.

A new funding round at a particular moment

The transaction brings Prosus into the company’s group of leading shareholders. The Dutch group, which specialises in international technology investments, is leading a financing combining new capital with the sale of existing shares, alongside established investors including Index Ventures and Teachers’ Venture Growth.

In March, Alan had already announced approximately €100 million in financing to support its European expansion. Just a few months later, a new round almost five times larger would further strengthen the company’s financial resources.

Companies generally return to the market this quickly in one of two situations: growth is accelerating far beyond expectations, or their financing requirements have proved greater than anticipated. The indicators published by Alan suggest a third explanation instead: the company is taking advantage of its position of strength to secure resources ahead of a new phase of development.

The fundamentals no longer tell the story of a startup seeking funding

Over the past decade, Alan has established itself as one of Europe’s leading digital health insurance companies. It now reports more than 1.1 million members, close to €800 million in annualised recurring revenue, year-on-year growth of 53% and a target of passing the symbolic €1 billion ARR threshold before the end of 2026.

France, which still represents most of its business, is now profitable. The company has also won several major contracts, including one with the French Ministry for the Economy and Finance, confirming its ability to compete with established providers in large-scale tenders.

The situation remains different at group level, where international expansion continues to weigh on consolidated results.

A new relationship with capital

During the first years of their existence, startups raise money to finance their development. The capital is used to recruit employees, build products, acquire customers or absorb losses.

Beyond a certain threshold, however, the logic changes. Once revenue becomes sufficiently substantial and growth remains strong, fundraising no longer responds solely to a financial need. Capital becomes a strategic asset.

Companies such as Stripe, Databricks and SpaceX have raised considerable sums despite already operating substantial businesses. Their objective was no longer simply to finance their operations, but to accelerate their trajectory and preserve their lead over competitors.

Buying time more than money

What can an additional €480 million actually provide when a company is already approaching €1 billion in recurring revenue?

The first answer is international expansion. Unlike a SaaS vendor, Alan operates in an industry where every country has its own regulatory framework, healthcare system, partners and operational constraints. Launching in Belgium, Spain or Canada is not simply a matter of translating an interface or opening a sales office.

Each new market requires regulatory investment, local teams, medical partnerships and product adaptation. Substantial cash reserves allow the company to pursue several launches simultaneously without continually having to choose between competing priorities.

The second answer concerns artificial intelligence. Alan does not develop large language models. It is, however, gradually integrating AI across its entire value chain: contract pricing, reimbursement management, request processing, patient guidance, appointment booking and conversational assistance.

This strategy requires continuous investment in infrastructure, data, engineering teams and the integration of new models. Here again, ready access to capital accelerates execution.

Finally, such financial resources open up other possibilities: targeted acquisitions, market consolidation, strategic partnerships or preparation for a future IPO, without depending on short-term market conditions.

On this point, Alan CEO Jean-Charles Samuelian told us: “We will continue accelerating our expansion in Europe and beyond, prepare further acquisitions and maintain our investment in artificial intelligence.”

Why Prosus, and why now?

The choice of Prosus is also significant. The Amsterdam-listed group, majority-owned by South Africa’s Naspers, has become one of the world’s most active technology investors. Its portfolio includes consumer platforms, e-commerce companies, fintechs and digital businesses operating at considerable scale, including Tencent, Delivery Hero and Dott.

Through Alan, Prosus is backing a new generation of European champions: genuine platforms combining software, healthcare services, artificial intelligence and digital distribution.

Fahd Beg, Chief Investment Officer at Prosus Group, said: “Healthcare is one of the sectors with the greatest potential for transformation through artificial intelligence. Alan has developed a unique platform in which insurance, prevention and support throughout the care journey reinforce one another to deliver a seamless and integrated healthcare experience. We are delighted to support Alan in this new phase of development and to accelerate its international expansion by drawing on the expertise and resources of our ecosystem.”

Speaking to FW.MEDIA, Jean-Charles Samuelian added: “We chose Prosus because they take an extremely long-term view, but also because they have a very deep ecosystem approach across many geographies, which can support our expansion. They are also highly advanced in artificial intelligence through their large commerce model, and very strong in consumer markets, which resonates with us.”

The questions Alan must now answer

The first naturally concerns international expansion. Close to 80% of Alan’s revenue still comes from France. The company’s ability to reach the next level will depend on whether it can replicate its model across several major European markets.

The second concerns the use of capital. Will the company focus exclusively on organic growth, or will it also seek to accelerate through acquisitions?

After conquering the French market and accelerating its European development, another question emerges: is Alan building a European health insurance champion, or laying the foundations for a genuinely global company?

Finally, this funding round could represent another step towards a future liquidity event. With a valuation of €5.5 billion and a target of more than €1 billion in recurring revenue, Alan is gradually approaching the profile of a major technology company capable of considering an IPO when market conditions are favourable.